this includes , but is not limited to , the humoral immune defect in common variable immunodeficiency , x-linked agammaglobulinemia , congenital agammaglobulinemia , wiskott-aldrich syndrome and severe combined immunodeficiency . these pis are a group of genetic disorders . based on recent estimates , these disorders are no longer considered to be very rare , with as many as one in every 1,200 people in the united states having some form of pi.bpc had originally received fda approval for bivigam on december 19 , 2012 , prior to our acquisition of btbu , and product sales had commenced in the first quarter of 2013. on may 9 , 2019 , the fda approved the prior approval supplement ( the “ pas ” ) for the use of our ivig manufacturing process , thereby enabling us to re-launch and commercialize this product in the united states . we resumed production of bivigam during the fourth quarter of 2017 after the closing of the biotest transaction and commercial production is ongoing , using our fda-approved ivig manufacturing process under u.s. department of health and human services ( “ hhs ” ) license no . 2019. the commercial re-launch and first commercial sales commenced in august of 2019. asceniv asceniv is a plasma-derived ivig that contains naturally occurring polyclonal antibodies , which are proteins that are used by the body 's immune system to neutralize microbes , such as bacteria and viruses and prevent against infection and disease . we manufacture asceniv under a hhs license no . 2019 using a process known as fractionation . as part of our proprietary manufacturing process for asceniv , we leverage our unique , patented plasma donor screening methodology and tailored plasma pooling design , which blends normal source plasma and plasma from donors tested to have high levels of neutralizing titers to rsv using our proprietary microneutralization assay . we are able to identify the high titer plasma that meets our internal specifications for asceniv with our patented testing assay . this type of high titer plasma is typically found in less than 10 % of the total donor collection samples we test . asceniv is approved for the treatment of pidd , a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents ( 12 to 17 years of age ) . our pivotal phase 3 clinical trial in 59 pidd patients met the primary endpoint of no serious bacterial infections reported during 12 months of treatment . secondary efficacy endpoints further demonstrated the benefits of asceniv in the low incidence of infection , therapeutic antibiotic use , days missed from work/school/daycare and unscheduled medical visits and hospitalizations . we believe this clinical data together with the fda approval for the treatment of pidd better positions adma to further evaluate asceniv in immune-compromised patients infected with or at-risk for rsv infection . we plan to work with the fda and the immunology and infectious disease community to design a clinical trial to evaluate the use of asceniv in this patient population in the near future . commercial sales of asceniv commenced in october of 2019. nabi-hb nabi-hb is a hyperimmune globulin that is rich in antibodies to the hepatitis b virus . nabi-hb is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a hepatitis b vaccine . nabi-hb is indicated for the treatment of acute exposure to blood containing hbsag , prenatal exposure of infants born to hbsag-positive mothers , sexual exposure to hbsag-positive persons and household exposure to persons with acute hepatitis b virus infection in specific , listed settings . hepatitis b is a potentially life-threatening liver infection caused by the hepatitis b virus . it is a major global health problem . it can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer . nabi-hb has a well-documented record of long-term safety and effectiveness since its initial market introduction . fda approval for nabi-hb was received on march 24 , 1999. biotest acquired nabi-hb from nabi biopharmaceuticals in 2007. production of nabi-hb at the boca facility has continued under our leadership since the third quarter of 2017. in early 2018 , we received authorization from the fda for the release of our first commercial batch of nabi-hb for commercial distribution in the u.s. and continue to manufacture under hhs license no . 2019 . 53 results of operations critical accounting policies and estimates this management 's discussion and analysis of financial condition and results of operations is based on our consolidated financial statements , which have been prepared in accordance with accounting principles generally accepted in the united states of america ( “ u.s . gaap ” ) . the preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets , liabilities , revenues and expenses . on an ongoing basis , we evaluate these estimates and assumptions , including those described below . we base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances . these estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources . actual results and experiences may differ materially from these estimates . significant estimates include the realizable value of accounts receivable , valuation of inventory , assumptions used in the fair value of awards granted under our equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for our deferred tax assets . some of the estimates and assumptions we have to make under u.s. gaap require difficult , subjective and or complex judgments about matters that are inherently uncertain and , as a result , actual results could differ from those estimates . story_separator_special_tag selling , general and administrative expenses sg & a was $ 25.9 million for the year ended december 31 , 2019 , an increase of $ 3.4 million as compared to the year ended december 31 , 2018. the increase reflects professional services of $ 1.8 million in 2019 related to enhancements to our information technology and customer support infrastructure necessary to support our overall growth and commercialization plans , as well as $ 0.9 million of higher employee related expenses due to increased headcount , increased marketing expenses of $ 0.4 million resulting from new product launches and $ 0.3 million of increased insurance expense . amortization of intangibles amortization expense for intangible assets acquired in the biotest transaction was $ 0.8 million for the years ended december 31 , 2019 and 2018. loss from operations our operating loss was $ 41.4 million for the year ended december 31 , 2019 , as compared to $ 60.3 million for the year ended december 31 , 2018. the decrease was mainly due to the increase in revenues and to decreases in cost of product revenue and other operating expenses aggregating to $ 6.5 million . interest expense interest expense was $ 9.0 million for the year ended december 31 , 2019 , as compared to $ 5.5 million for the year ended december 31 , 2018. the increase reflects a higher average debt principal balance carried in 2019 as compared to 2018 due to the senior debt refinancing transaction in february 2019 and the amendment to our senior credit facility in may 2019 ( see “ liquidity and capital resources ” ) , which resulted in additional debt principal of $ 42.5 million . story_separator_special_tag href= `` https : //www.sec.gov/archives/edgar/data/0001368514/000119380520000348/ # toc `` style= `` font-style : italic `` > in february 2020 , we completed an underwritten public offering of 27,025,000 shares of our common stock and received net proceeds , after underwriting discounts and other expenses associated with the offering , of approximately $ 88.5 million . the proceeds from this offering are expected to be used ( i ) for the procurement of raw materials for the manufacturing of bivigam and asceniv ; ( ii ) to support the ongoing commercial sales of bivigam and asceniv ; ( iii ) to expand the manufacturing capacity of our boca facility and enhance our supply chain capabilities ; ( iv ) to expand our plasma collection facility network ; ( v ) for research and development and business development opportunities ; and ( vi ) for general corporate purposes and other capital expenditures . on may 21 , 2019 , we issued 12,937,500 shares of our common stock in an underwritten public offering for gross proceeds of $ 51.75 million , before deducting underwriting discounts and commissions and other offering expenses payable by us . the net proceeds of $ 48.4 million from the offering have been used ( i ) to support the commercial launch of asceniv , which commenced in october 2019 , ( ii ) for the commercial re-launch of bivigam , ( iii ) to expand the manufacturing capacity of the boca facility , ( iv ) for the procurement of raw materials for the manufacturing of asceniv and bivigam , ( v ) to expand our plasma collection facility network ; and ( vi ) for general corporate purposes and other capital expenditures . on february 11 , 2019 ( the “ perceptive closing date ” ) , we and all of our subsidiaries entered into the perceptive credit agreement with perceptive . the perceptive credit agreement provided for the perceptive credit facility in a principal amount of up to $ 72.5 million , comprised of ( i ) the perceptive tranche i loan in the principal amount of $ 45.0 million , and ( ii ) the perceptive tranche ii loan in the principal amount of up to $ 27.5 million , but no less than $ 10.0 million . the perceptive credit facility has a maturity date of march 1 , 2022 ( the “ perceptive maturity date ” ) , subject to acceleration pursuant to the perceptive credit agreement , including upon an event of default ( as defined in the perceptive credit agreement ) . on the perceptive closing date , we used $ 30.0 million of the perceptive tranche i loan to terminate and pay in full all of the outstanding obligations under our previously existing credit agreement with marathon healthcare finance fund , l.p. ( “ marathon ” ) ( the “ marathon credit facility ” ) that we entered into in october 2017. we also used proceeds from the perceptive tranche i loan to ( i ) pay a deferred facility fee to marathon of $ 2.8 million , ( ii ) pay a prepayment penalty to marathon of $ 6.5 million , ( iii ) pay outstanding accrued interest to marathon of $ 0.7 million and ( iv ) pay certain fees and expenses incurred in connection with the perceptive credit facility of approximately $ 1.5 million . in addition , on the perceptive closing date , marathon released to us the $ 4.0 million of cash held in a debt service reserve account , per the terms of the marathon credit facility . as consideration for the perceptive credit agreement , we issued to perceptive , on the perceptive closing date , a warrant to purchase 1,360,000 shares of our common stock ( the “ perceptive warrant ” ) . the perceptive warrant has an exercise price equal to $ 3.28 per share , which is equal to the trailing 10-day volume weighted average price ( “ vwap ” ) of our common stock on the business day immediately prior to the perceptive closing date multiplied by 1.15. we valued the perceptive warrant at $ 2.7 million as of the perceptive closing date , and it has an expiration date of february 11 , 2029.

loss on extinguishment of debt in connection with the refinancing of our senior credit facility in 2019 , we incurred a loss on the extinguishment debt for the retirement of our previously existing credit facility , consisting of a $ 6.5 million prepayment penalty , and the write-off of $ 3.5 million of unamortized debt discount related to the previous credit facility . gain on transfer of plasma center assets as part of the purchase price for the biotest assets , we agreed to transfer two of our plasma collection centers to bpc effective january 1 , 2019. we had estimated the combined fair value of the two facilities to be $ 12.6 million , and we recorded a liability in our financial statements for this amount as of the date of the biotest transaction . on january 1 , 2019 , the two plasma collection facilities were transferred to bpc and we recorded a gain on this transfer in the amount of $ 11.5 million , which reflects the derecognition of the obligation to transfer ownership of the two facilities net of the carrying value of the assets associated with these facilities , primarily property and equipment and inventory , in the amount of $ 1.1 million . net loss net loss was $ 48.3 million for the year ended december 31 , 2019 , as compared to $ 65.7 million for the year ended december 31 , 2018. the reduction in net loss of $ 17.5 million was due to the decrease in operating loss and the gain on transfer of plasma center assets , partially offset by the loss on extinguishment of debt and the increased interest expense .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```loss on extinguishment of debt in connection with the refinancing of our senior credit facility in 2019 , we incurred a loss on the extinguishment debt for the retirement of our previously existing credit facility , consisting of a $ 6.5 million prepayment penalty , and the write-off of $ 3.5 million of unamortized debt discount related to the previous credit facility . gain on transfer of plasma center assets as part of the purchase price for the biotest assets , we agreed to transfer two of our plasma collection centers to bpc effective january 1 , 2019. we had estimated the combined fair value of the two facilities to be $ 12.6 million , and we recorded a liability in our financial statements for this amount as of the date of the biotest transaction . on january 1 , 2019 , the two plasma collection facilities were transferred to bpc and we recorded a gain on this transfer in the amount of $ 11.5 million , which reflects the derecognition of the obligation to transfer ownership of the two facilities net of the carrying value of the assets associated with these facilities , primarily property and equipment and inventory , in the amount of $ 1.1 million . net loss net loss was $ 48.3 million for the year ended december 31 , 2019 , as compared to $ 65.7 million for the year ended december 31 , 2018. the reduction in net loss of $ 17.5 million was due to the decrease in operating loss and the gain on transfer of plasma center assets , partially offset by the loss on extinguishment of debt and the increased interest expense .
```    
 Suspicious Activity Report : this includes , but is not limited to , the humoral immune defect in common variable immunodeficiency , x-linked agammaglobulinemia , congenital agammaglobulinemia , wiskott-aldrich syndrome and severe combined immunodeficiency . these pis are a group of genetic disorders . based on recent estimates , these disorders are no longer considered to be very rare , with as many as one in every 1,200 people in the united states having some form of pi.bpc had originally received fda approval for bivigam on december 19 , 2012 , prior to our acquisition of btbu , and product sales had commenced in the first quarter of 2013. on may 9 , 2019 , the fda approved the prior approval supplement ( the “ pas ” ) for the use of our ivig manufacturing process , thereby enabling us to re-launch and commercialize this product in the united states . we resumed production of bivigam during the fourth quarter of 2017 after the closing of the biotest transaction and commercial production is ongoing , using our fda-approved ivig manufacturing process under u.s. department of health and human services ( “ hhs ” ) license no . 2019. the commercial re-launch and first commercial sales commenced in august of 2019. asceniv asceniv is a plasma-derived ivig that contains naturally occurring polyclonal antibodies , which are proteins that are used by the body 's immune system to neutralize microbes , such as bacteria and viruses and prevent against infection and disease . we manufacture asceniv under a hhs license no . 2019 using a process known as fractionation . as part of our proprietary manufacturing process for asceniv , we leverage our unique , patented plasma donor screening methodology and tailored plasma pooling design , which blends normal source plasma and plasma from donors tested to have high levels of neutralizing titers to rsv using our proprietary microneutralization assay . we are able to identify the high titer plasma that meets our internal specifications for asceniv with our patented testing assay . this type of high titer plasma is typically found in less than 10 % of the total donor collection samples we test . asceniv is approved for the treatment of pidd , a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents ( 12 to 17 years of age ) . our pivotal phase 3 clinical trial in 59 pidd patients met the primary endpoint of no serious bacterial infections reported during 12 months of treatment . secondary efficacy endpoints further demonstrated the benefits of asceniv in the low incidence of infection , therapeutic antibiotic use , days missed from work/school/daycare and unscheduled medical visits and hospitalizations . we believe this clinical data together with the fda approval for the treatment of pidd better positions adma to further evaluate asceniv in immune-compromised patients infected with or at-risk for rsv infection . we plan to work with the fda and the immunology and infectious disease community to design a clinical trial to evaluate the use of asceniv in this patient population in the near future . commercial sales of asceniv commenced in october of 2019. nabi-hb nabi-hb is a hyperimmune globulin that is rich in antibodies to the hepatitis b virus . nabi-hb is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a hepatitis b vaccine . nabi-hb is indicated for the treatment of acute exposure to blood containing hbsag , prenatal exposure of infants born to hbsag-positive mothers , sexual exposure to hbsag-positive persons and household exposure to persons with acute hepatitis b virus infection in specific , listed settings . hepatitis b is a potentially life-threatening liver infection caused by the hepatitis b virus . it is a major global health problem . it can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer . nabi-hb has a well-documented record of long-term safety and effectiveness since its initial market introduction . fda approval for nabi-hb was received on march 24 , 1999. biotest acquired nabi-hb from nabi biopharmaceuticals in 2007. production of nabi-hb at the boca facility has continued under our leadership since the third quarter of 2017. in early 2018 , we received authorization from the fda for the release of our first commercial batch of nabi-hb for commercial distribution in the u.s. and continue to manufacture under hhs license no . 2019 . 53 results of operations critical accounting policies and estimates this management 's discussion and analysis of financial condition and results of operations is based on our consolidated financial statements , which have been prepared in accordance with accounting principles generally accepted in the united states of america ( “ u.s . gaap ” ) . the preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets , liabilities , revenues and expenses . on an ongoing basis , we evaluate these estimates and assumptions , including those described below . we base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances . these estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources . actual results and experiences may differ materially from these estimates . significant estimates include the realizable value of accounts receivable , valuation of inventory , assumptions used in the fair value of awards granted under our equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for our deferred tax assets . some of the estimates and assumptions we have to make under u.s. gaap require difficult , subjective and or complex judgments about matters that are inherently uncertain and , as a result , actual results could differ from those estimates . story_separator_special_tag selling , general and administrative expenses sg & a was $ 25.9 million for the year ended december 31 , 2019 , an increase of $ 3.4 million as compared to the year ended december 31 , 2018. the increase reflects professional services of $ 1.8 million in 2019 related to enhancements to our information technology and customer support infrastructure necessary to support our overall growth and commercialization plans , as well as $ 0.9 million of higher employee related expenses due to increased headcount , increased marketing expenses of $ 0.4 million resulting from new product launches and $ 0.3 million of increased insurance expense . amortization of intangibles amortization expense for intangible assets acquired in the biotest transaction was $ 0.8 million for the years ended december 31 , 2019 and 2018. loss from operations our operating loss was $ 41.4 million for the year ended december 31 , 2019 , as compared to $ 60.3 million for the year ended december 31 , 2018. the decrease was mainly due to the increase in revenues and to decreases in cost of product revenue and other operating expenses aggregating to $ 6.5 million . interest expense interest expense was $ 9.0 million for the year ended december 31 , 2019 , as compared to $ 5.5 million for the year ended december 31 , 2018. the increase reflects a higher average debt principal balance carried in 2019 as compared to 2018 due to the senior debt refinancing transaction in february 2019 and the amendment to our senior credit facility in may 2019 ( see “ liquidity and capital resources ” ) , which resulted in additional debt principal of $ 42.5 million . story_separator_special_tag href= `` https : //www.sec.gov/archives/edgar/data/0001368514/000119380520000348/ # toc `` style= `` font-style : italic `` > in february 2020 , we completed an underwritten public offering of 27,025,000 shares of our common stock and received net proceeds , after underwriting discounts and other expenses associated with the offering , of approximately $ 88.5 million . the proceeds from this offering are expected to be used ( i ) for the procurement of raw materials for the manufacturing of bivigam and asceniv ; ( ii ) to support the ongoing commercial sales of bivigam and asceniv ; ( iii ) to expand the manufacturing capacity of our boca facility and enhance our supply chain capabilities ; ( iv ) to expand our plasma collection facility network ; ( v ) for research and development and business development opportunities ; and ( vi ) for general corporate purposes and other capital expenditures . on may 21 , 2019 , we issued 12,937,500 shares of our common stock in an underwritten public offering for gross proceeds of $ 51.75 million , before deducting underwriting discounts and commissions and other offering expenses payable by us . the net proceeds of $ 48.4 million from the offering have been used ( i ) to support the commercial launch of asceniv , which commenced in october 2019 , ( ii ) for the commercial re-launch of bivigam , ( iii ) to expand the manufacturing capacity of the boca facility , ( iv ) for the procurement of raw materials for the manufacturing of asceniv and bivigam , ( v ) to expand our plasma collection facility network ; and ( vi ) for general corporate purposes and other capital expenditures . on february 11 , 2019 ( the “ perceptive closing date ” ) , we and all of our subsidiaries entered into the perceptive credit agreement with perceptive . the perceptive credit agreement provided for the perceptive credit facility in a principal amount of up to $ 72.5 million , comprised of ( i ) the perceptive tranche i loan in the principal amount of $ 45.0 million , and ( ii ) the perceptive tranche ii loan in the principal amount of up to $ 27.5 million , but no less than $ 10.0 million . the perceptive credit facility has a maturity date of march 1 , 2022 ( the “ perceptive maturity date ” ) , subject to acceleration pursuant to the perceptive credit agreement , including upon an event of default ( as defined in the perceptive credit agreement ) . on the perceptive closing date , we used $ 30.0 million of the perceptive tranche i loan to terminate and pay in full all of the outstanding obligations under our previously existing credit agreement with marathon healthcare finance fund , l.p. ( “ marathon ” ) ( the “ marathon credit facility ” ) that we entered into in october 2017. we also used proceeds from the perceptive tranche i loan to ( i ) pay a deferred facility fee to marathon of $ 2.8 million , ( ii ) pay a prepayment penalty to marathon of $ 6.5 million , ( iii ) pay outstanding accrued interest to marathon of $ 0.7 million and ( iv ) pay certain fees and expenses incurred in connection with the perceptive credit facility of approximately $ 1.5 million . in addition , on the perceptive closing date , marathon released to us the $ 4.0 million of cash held in a debt service reserve account , per the terms of the marathon credit facility . as consideration for the perceptive credit agreement , we issued to perceptive , on the perceptive closing date , a warrant to purchase 1,360,000 shares of our common stock ( the “ perceptive warrant ” ) . the perceptive warrant has an exercise price equal to $ 3.28 per share , which is equal to the trailing 10-day volume weighted average price ( “ vwap ” ) of our common stock on the business day immediately prior to the perceptive closing date multiplied by 1.15. we valued the perceptive warrant at $ 2.7 million as of the perceptive closing date , and it has an expiration date of february 11 , 2029.

